Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Per company pipeline-
Innovation Pharma owns rights to Brilacidin, a de novo-designed defensin-mimetic drug candidate exhibiting anti-inflammatory and antimicrobial properties. Brilacidin has been evaluated in multiple clinical trials (over 500 patients treated to date), received special FDA designations and can be administered via various modes of delivery.
I share your thoughts. Leo reported in vitro and in vivo studies seeing positive results (there's that "p" word). Also it was reported that further testing was planned by NIH/NIAID-affiliated and other academic researchers. I also believe we have a good shot at a deal. Good luck to us all. Btw you own a substantial lot. Go BeaMed!
WAKEFIELD, MA / March 15, 2023 Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that based on positive findings new testing of Brilacidin in additional in vitro and in vivo models against hard-to-treat fungal pathogens is planned by NIH/NIAID-affiliated and other academic researchers. Brilacidin is the Company’s defensin mimetic drug candidate exhibiting antimicrobial and immunomodulatory properties.
Participants improving significantly is good to see. Thanks for posting video georgejjl.
Your not being selfish, investors yearn for IPIX to recover and do well. God Bless you in your recovery.
Many thanks frenchbroad. Looking forward to upcoming reports.
We don't know just how many submissions they have but I bet each submission could take at least 30 days for an answer and then if the FDA has questions that could take longer. Hopefully a final answer some time in June. All just a guess but I remember reading sometime back that the FDA can take 45 days to reply.
Wow sounds like Dr Missling has already had a good look at the data. Maybe we will see the full data release during AAIC in July.
Some will be sold for sure but it all depends on the gravity of the news that gets us there.
It's not just the ceo, you have directors and many scientific advisers standing behind the reports.
Guarantee my doctor of medicine wouldn't have the time.
Your right. Thanks for that.
If kips sold it would generate a form-4.
Just wonderful to hear. All improvements returned when going back on A-273.
Yes "progress towards commercialization" is conclusive. That choice of words is a far cry from needing another trial.
ANAVEX®2-73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS,
SHOWING STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN GLOBAL CLINICAL STUDY OF PATIENTS WITH EARLY ALZHEIMER’S DISEASE
What data/numbers are you looking for.
To start Rett syndrome approved this year. It's an unmet need. I see it moving through US regulatory fairly quickly. AZ could see approval in Australia yet this year.
Other than that. Nice tick up.
I see it's now $8.43.
This should explain his post, Dr. Randi J. Hagerman is very bullish on results seen in Anavex A-273 - https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171816711
Ask price by size
0.0198 x by 60000 shares
Volume
8,379
Agree, I believe there would be great appeal for a safe blood pressure medication that's non diuretic.
Thanks for posting cantwate. Having in vivo studies is progress to a higher level.
I believe Dr Missiling to be on the up and up and that's why I bought shares. Trading works both ways if company insiders found data not good wouldn't they be dumping as well.
My understanding is leadership schedule their buys by calendar date.
Message I got said said not excepting calls not that it was disconnected. 978-921-4125. Leo doesn't exude confidence in his business acumen that's for sure. I continue to hold but just don't have much interest in this thing anymore. Things can change with the right news beyond just testing.
4:17 Ready for commercialization. Just to hear Dr Missling say it WOW!
Battle of the mm's happening.
"New in vivo data in an A. fumigatus murine fungal keratitis model showed brilacidin reduced fungal burden and disease severity, while also improving corneal thickness compared to control. brilacidin-treated corneas harbored almost no viable fungus, suggesting the compound suppressed fungal proliferation within the cornea. Worldwide, on an annual basis, fungal keratitis affects up to 1.5 million people, of whom 75 percent may lose an eye and/or their sight".
You brought the proof frenchbroad.
More animal model testing planned
"Planned next steps in brilacidin antifungal research include extending in vitro and in vivo testing into additional clinical isolates and animal models, and publishing scientific findings. In collaboration with the NIH/NIAID’s mycology division, brilacidin also is to be screened in multiple fungal species to further characterize its broad-spectrum antifungal activity. Future updates are planned".
Not true. Multiple CNS trials have demonstrated and shown proof of A-273 efficacy. Now we wait for regulatory guidance.
I believe you should have at least equal education in order to say the findings are correct otherwise it just sounds good.
So you have A PhD degree in Biostatistics?.
You jumped the shark on saying cure. May hold potential as all other early studies.
Also at 16:55 min: "Structural and functional MRI" is "about to be released". If all data is included with MRI then we could see full results soon.
"6:45 min: Full AD 2b/3 data is still expected this year. This will include MRI, biomarkers, blood data, dose-dependent results of ALL measures including cognition, function, quality of life."
In the words of Reagan trust but verify. Her background is physics and deal making. Good combination.
Positive peer review. B likely to improve outcomes when combined with other drugs. BRI combined with CAS significantly clears A. fumigatus lung infection in an immunosuppressed murine model of invasive pulmonary aspergillosis.
BRI alone also decreases A. fumigatus fungal burden and ablates disease development in a murine model of fungal keratitis. Our results indicate that combinations of BRI and antifungal drugs in clinical use are likely to improve the treatment outcome of aspergillosis and other fungal infections.
Taken together, these results indicate that BRI is able to potentiate CAS activity for different human fungal pathogens, including C. neoformans. Interestingly, C. neoformans is very sensitive to BRI alone and BRI is fungicidal against this fungus. Thus, BRI is an alternative therapeutic against C. neoformans alone or in combination with CAS since it potentiates the latter’s activity into a fungicidal drug. BRI?+?CAS combination has also synergism against C. auris dramatically decreasing its viability.
Great find frenchbroad.
First of all how long will it take to get new updated data. Likely newly hired Dr Jin is working on it, although frustratingly slow.
"At this time some of your questions can
not be answered today, because new,
updated data will be available to us
in the near future"
The good ol days when thumbs ups were flying.
February 23, 2023 - Innovation Pharmaceuticals Visits BeaMed; New StingRay Laser System for Epilepsy and Brain Tumors Moving Toward FDA Submission. Go Stingray approval.
Whoa that's a huge list of nasty side effects and it was approved. If B had that long list they would be howling at the moon over it. I see tingling of the hands and feet or is it peripheral neuropathy..